Risk of second primary cancer from proton arc therapy of pediatric brain tumors

Proton arc therapy (PAT) is currently explored for clinical implementation, despite its associated low-dose bath. This study therefore aimed at evaluating the risk of radiation-induced second primary cancer (SPC) for PAT in pediatric brain tumor patients. Two brain-specific models for SPC induction...

Descripción completa

Detalles Bibliográficos
Autores principales: Toussaint, Laura, Indelicato, Daniel J, Muren, Ludvig P, Stokkevåg, Camilla H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465935/
https://www.ncbi.nlm.nih.gov/pubmed/37655121
http://dx.doi.org/10.1016/j.phro.2023.100480
_version_ 1785098774722379776
author Toussaint, Laura
Indelicato, Daniel J
Muren, Ludvig P
Stokkevåg, Camilla H
author_facet Toussaint, Laura
Indelicato, Daniel J
Muren, Ludvig P
Stokkevåg, Camilla H
author_sort Toussaint, Laura
collection PubMed
description Proton arc therapy (PAT) is currently explored for clinical implementation, despite its associated low-dose bath. This study therefore aimed at evaluating the risk of radiation-induced second primary cancer (SPC) for PAT in pediatric brain tumor patients. Two brain-specific models for SPC induction were applied in five cases to compare volumetric modulated arc therapy (VMAT), intensity modulated proton therapy (IMPT) and PAT surrogate plans. The PAT integral dose was reduced by a median of 29% compared to VMAT, and 17% compared to IMPT. For both models, the estimated SPC risks were consistently the lowest for PAT.
format Online
Article
Text
id pubmed-10465935
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104659352023-08-31 Risk of second primary cancer from proton arc therapy of pediatric brain tumors Toussaint, Laura Indelicato, Daniel J Muren, Ludvig P Stokkevåg, Camilla H Phys Imaging Radiat Oncol Short Communication Proton arc therapy (PAT) is currently explored for clinical implementation, despite its associated low-dose bath. This study therefore aimed at evaluating the risk of radiation-induced second primary cancer (SPC) for PAT in pediatric brain tumor patients. Two brain-specific models for SPC induction were applied in five cases to compare volumetric modulated arc therapy (VMAT), intensity modulated proton therapy (IMPT) and PAT surrogate plans. The PAT integral dose was reduced by a median of 29% compared to VMAT, and 17% compared to IMPT. For both models, the estimated SPC risks were consistently the lowest for PAT. Elsevier 2023-08-10 /pmc/articles/PMC10465935/ /pubmed/37655121 http://dx.doi.org/10.1016/j.phro.2023.100480 Text en © 2023 The Authors. Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Short Communication
Toussaint, Laura
Indelicato, Daniel J
Muren, Ludvig P
Stokkevåg, Camilla H
Risk of second primary cancer from proton arc therapy of pediatric brain tumors
title Risk of second primary cancer from proton arc therapy of pediatric brain tumors
title_full Risk of second primary cancer from proton arc therapy of pediatric brain tumors
title_fullStr Risk of second primary cancer from proton arc therapy of pediatric brain tumors
title_full_unstemmed Risk of second primary cancer from proton arc therapy of pediatric brain tumors
title_short Risk of second primary cancer from proton arc therapy of pediatric brain tumors
title_sort risk of second primary cancer from proton arc therapy of pediatric brain tumors
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465935/
https://www.ncbi.nlm.nih.gov/pubmed/37655121
http://dx.doi.org/10.1016/j.phro.2023.100480
work_keys_str_mv AT toussaintlaura riskofsecondprimarycancerfromprotonarctherapyofpediatricbraintumors
AT indelicatodanielj riskofsecondprimarycancerfromprotonarctherapyofpediatricbraintumors
AT murenludvigp riskofsecondprimarycancerfromprotonarctherapyofpediatricbraintumors
AT stokkevagcamillah riskofsecondprimarycancerfromprotonarctherapyofpediatricbraintumors

Ejemplares similares